Atlas Trials

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Clinical trial NCT05563844 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05563844
Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma,DLBCL
Start date
2022-11-08
Primary completion
2026-12-30
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.